Understanding the differences between two types of mutations in a protein linked to blood cancers.
The Pathophysiology of Type 1 Versus Type 2 Mutant Calreticulin-Drivenmyeloproliferative Neoplasms
This study is looking at how different mutations in a protein called calreticulin affect the progression of myeloproliferative neoplasms (MPNs) and aims to find new treatments, inviting patients with MPNs to help by participating in genetic testing and check-ups.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11158469 on NIH RePORTER |
What this research studies
This research investigates the pathophysiology of myeloproliferative neoplasms (MPNs), specifically focusing on the differences between type 1 and type 2 mutations in the calreticulin protein. By examining how these mutations affect disease progression and patient outcomes, the study aims to identify potential new therapies that could more effectively treat these conditions. The approach includes analyzing the genetic and molecular mechanisms behind these mutations and their impact on signaling pathways involved in blood cell production. Patients with MPNs may have the opportunity to contribute to this research through genetic testing and clinical assessments.
Who could benefit from this research
Good fit: Ideal candidates for participation are individuals diagnosed with myeloproliferative neoplasms, particularly those with calreticulin mutations.
Not a fit: Patients without myeloproliferative neoplasms or those with different underlying genetic causes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that improve treatment outcomes for patients with myeloproliferative neoplasms.
How similar studies have performed: Previous research has shown promising results in understanding the role of genetic mutations in blood cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Elf, Shannon Elisabeth — University of Utah
- Study coordinator: Elf, Shannon Elisabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.